keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous erythropoietin

keyword
https://www.readbyqxmd.com/read/27640183/erythropoietin-does-not-activate-erythropoietin-receptor-signaling-or-lipolytic-pathways-in-human-subcutaneous-white-adipose-tissue-in-vivo
#1
Britt Christensen, Birgitte Nellemann, Jens Otto L Jørgensen, Steen B Pedersen, Niels Jessen
BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented. We therefore investigated the effects of acute and prolonged Epo exposure on human WAT in vivo. METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha...
2016: Lipids in Health and Disease
https://www.readbyqxmd.com/read/27611985/recombinant-human-erythropoietin-improves-functional-recovery-in-patients-with-severe-traumatic-brain-injury-a-randomized-double-blind-and-controlled-clinical-trial
#2
Zhong-Min Li, Yi-Lei Xiao, Jian-Xin Zhu, Feng-Yang Geng, Chuan-Jun Guo, Zong-Lei Chong, Le-Xin Wang
OBJECTIVE: To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury. METHODS: One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n=79) and control group (n=80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment...
November 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/27566219/efficacy-and-safety-of-adjuvant-recombinant-human-erythropoietin-and-ferrous-sulfate-as-treatment-for-iron-deficiency-anemia-during-the-third-trimester-of-pregnancy
#3
Luis Rodrigo Sanchez-Gonzalez, Simón Enrique Castro-Melendez, Alejandra Cristina Angeles-Torres, Nohemi Castro-Cortina, Alfredo Escobar-Valencia, Alejandro Quiroga-Garza
PURPOSE: Gestational anemia increases the incidence of maternal and fetal complications. Adjuvant recombinant human erythropoietin (rHuEPO) has been used in patients who refuse blood transfusions, have a low response to treatment with iron sulfate, have limited time before birth, or have other illnesses that complicate the anemia. We demonstrated that the use of adjuvant rHuEPO with iron sulfate reduces the anemia time period and is innocuous to the fetus. METHOD: An experimental longitudinal prospective study; 100 pregnant women in their third trimester were included...
October 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27478604/pure-red-cell-aplasia-induced-by-epoetin-zeta
#4
Vincenzo Panichi, Guido Ricchiuti, Alessia Scatena, Lucia Del Vecchio, Francesco Locatelli
Pure red cell aplasia (PRCA) may develop in patients with chronic kidney disease receiving erythropoiesis-stimulating agents (ESA). We report on a 72-year-old patient who developed hypo-proliferative anaemia unresponsive to ESA following the administration of epoetin zeta subcutaneously for 7 months. On the basis of severe isolated hypoplasia of the erythroid line in the bone marrow and high-titre neutralizing anti-erythropoietin antibodies (Ab), a diagnosis of Ab-mediated PRCA was made. Epoetin zeta was discontinued and the patient was given steroids...
August 2016: Clinical Kidney Journal
https://www.readbyqxmd.com/read/27473384/pharmacokinetic-and-pharmacodynamic-equivalence-of-epoetin-hospira-and-epogen-after-single-subcutaneous-doses-to-healthy-male-subjects
#5
Dennis Stalker, Susan Reid, Atulkumar Ramaiya, Wayne A Wisemandle, Nancy E Martin
PURPOSE: The purpose of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of single 100 U/kg subcutaneous doses of Epoetin Hospira and Epogen in healthy male subjects as part of an overall program to demonstrate biosimilarity of Epoetin Hospira to the reference product Epogen. METHODS: This single-center, open-label, randomized, 2-period, crossover study was conducted in 81 healthy male subjects. Subjects were randomized to Sequence 1, in which they received 100 U/kg of Epoetin Hospira or to sequence 2, in which they received 100 U/kg Epogen subcutaneously in the first study period and the alternative treatment in the second study period...
August 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27452792/oxidative-stress-induces-the-decline-of-brain-epo-expression-in-aging-rats
#6
Xu Li, Yubao Chen, Siying Shao, Qing Tang, Weihai Chen, Yi Chen, Xiaoyu Xu
Brain Erythropoietin (EPO), an important neurotrophic factor and neuroprotective factor, was found to be associated with aging. Studies found EPO expression was significantly decreased in the hippocampus of aging rat compared with that of the youth. But mechanisms of the decline of the brain EPO during aging remain unclear. The present study utilized a d-galactose (d-gal)-induced aging model in which the inducement of aging was mainly oxidative injury, to explore underlying mechanisms for the decline of brain EPO in aging rats...
October 2016: Experimental Gerontology
https://www.readbyqxmd.com/read/27441542/clinical-application-of-recombinant-erythropoietin-in-beta-thalassaemia-intermedia
#7
Ch Asadov, Z Alimirzoyeva, M Hasanova, T Mammadova, A Shirinova
Research objective is to study the efficacy of recombinant erythropoietin (epoetin alfa) as alternative method of treatment beta-thalassemia intermedia. Study involved 58 patients with beta-thalassemia intermedia (23 women and 35 men). In all observed patients was defined levels of hemoglobin (Hb), red blood cells (RBC), erythrocyte indexes (MCV, MCH, MCHC), hemoglobin fractions (HbA, HbA2, HbF), serum ferritin, serum erythropoietin before and after administrated rEPO. All patients received rEPO during 6 month at the dose - 10000 IU subcutaneously...
June 2016: Georgian Medical News
https://www.readbyqxmd.com/read/27348783/increased-bone-formation-in-a-rabbit-long-bone-defect-model-after-single-local-and-single-systemic-application-of-erythropoietin
#8
Georg W Omlor, Kerstin Kleinschmidt, Simone Gantz, Anja Speicher, Thorsten Guehring, Wiltrud Richter
Background and purpose - Delayed bone healing with non-union is a common problem. Further options to increase bone healing together with surgery are needed. We therefore evaluated a 1-dose single application of erythropoietin (EPO), applied either locally to the defect or systemically during surgery, in a critical-size rabbit long-bone defect. Material and methods - 19 New Zealand White rabbits received a 15-mm defect in the radius diaphysis. An absorbable gelatin sponge was soaked with saline (control group and systemic treatment group) or EPO (local treatment group) and implanted into the gap...
August 2016: Acta Orthopaedica
https://www.readbyqxmd.com/read/27348021/a-cluster-of-epoetin-associated-pure-red-cell-aplasia-clinical-features-and-the-possible-association-of-hla-drb1-12-02
#9
Chuen Wen Tan, Wei-Chuen Tan-Koi, Jennifer Ng, Choong Meng Chan, William Ying Khee Hwang
Antibody-mediated pure red cell aplasia is a rare but serious complication in chronic kidney disease patients receiving recombinant human erythropoietin (r-HuEpo). Between April 2012 and May 2013, eight such cases were reported in our institution. Their clinical features were reviewed and their HLA alleles were compared with those of healthy controls. All patients were exposed to epoetin alfa (Eprex(®)) with polysorbate-80 as stabilizer via subcutaneous route with a mean age of 61.9 years and mean exposure of 11...
June 27, 2016: Pharmacogenomics
https://www.readbyqxmd.com/read/27344167/local-and-systemic-renin-angiotensin-system-participates-in-cardiopulmonary-renal-interactions-in-monocrotaline-induced-pulmonary-hypertension-in-the-rat
#10
Eva Malikova, Kristina Galkova, Peter Vavrinec, Diana Vavrincova-Yaghi, Zuzana Kmecova, Peter Krenek, Jan Klimas
Renin-angiotensin system (RAS) is one of the pathophysiological mechanisms in heart failure. Recently, involvement of the kidney in the disease progression has been proposed in patients with pulmonary arterial hypertension (PAH). We hypothesized that local and systemic RAS could be the central regulators of cardiopulmonary-renal interactions in experimental monocrotaline-induced pulmonary hypertension (PH) in rats. Male 12-week-old Wistar rats were injected subcutaneously with monocrotaline (60 mg/kg). The experiment was terminated 4 weeks after monocrotaline administration...
July 2016: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/27238922/administer-but-do-not-dispense-effect-of-change-in-medication-handling-by-nurses-on-outcomes-of-home-dialysis-patients
#11
Michael E Ullian, Cynthia A Martin, David M Ullian
BACKGROUND: To come into compliance with South Carolina statute, we changed how nurses handle medications (antibiotics, erythropoietin [EPO], calcitriol and heparin) in our outpatient home dialysis clinic. Nurses continued to administer medications in the clinic but no longer dispensed medications for patients to take home; instead, medications were dispensed from pharmacies to the patients by mail. We hypothesized that the abovementioned change in medication handling worsened clinical outcomes...
June 2016: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/27233796/clinical-trial-of-erythropoietin-in-young-children-with-cerebral-palsy
#12
Kye Hee Cho, Kyunghoon Min, Seung Hoon Lee, SunHee Lee, SeongSoo A An, MinYoung Kim
This study was conducted to assess the safety and efficacy of recombinant human erythropoietin in young children with cerebral palsy aged between 6 months and 3 years. All participants received subcutaneous recombinant human erythropoietin and 8 weeks of rehabilitation therapy. Adverse events, changes of vital signs, and hematologic tests were monitored up to 8 weeks postinjection. Functional measures of development at 4 and 8 weeks postinjection were compared with baseline values, and improvements were compared with those of an age-matched historical control group...
September 2016: Journal of Child Neurology
https://www.readbyqxmd.com/read/27195774/ferric-carboxymaltose-with-or-without-erythropoietin-in-anemic-patients-with-hip-fracture-a-randomized-clinical-trial
#13
Máximo Bernabeu-Wittel, Manuel Romero, Manuel Ollero-Baturone, Reyes Aparicio, José Murcia-Zaragoza, Manuel Rincón-Gómez, Rafael Monte-Secades, María Melero-Bascones, Clara M Rosso, Alberto Ruiz-Cantero
BACKGROUND: The increasing incidence of osteoporotic hip fracture (HF) has raised the requirements of red blood cell (RBC) transfusions, whereas this scarce resource may cause morbidity and mortality. STUDY DESIGN AND METHODS: This study was a multicenter, randomized, double-blind, clinical trial that aimed to assess efficacy of ferric carboxymaltose (FCM) with or without erythropoietin (EPO) in reducing RBC transfusion in the perioperative period of HF. Participants (patients > 65 years admitted with HF and hemoglobin [Hb] levels of 90-120 g/L) were randomly assigned to receive a preoperative single dose of 1 g of FCM (short intravenous [IV] infusion over 15 min), plus 40,000 IU of subcutaneous EPO (EPOFE arm); versus 1 g of IV FCM plus subcutaneous placebo (FE arm); and versus IV and subcutaneous placebo (placebo arm)...
September 2016: Transfusion
https://www.readbyqxmd.com/read/27178833/dynamics-of-the-erythropoiesis-stimulating-agent-resistance-index-in-incident-hemodiafiltration-and-high-flux-hemodialysis-patients
#14
Daniele Marcelli, Inga Bayh, José I Merello, Pedro Ponce, Alex Heaton, Fatih Kircelli, Charles Chazot, Attilio Di Benedetto, Cristina Marelli, Erzsebet Ladanyi, Miroslaw Kroczak, Stefano Stuard, Aileen Grassmann, Laura Scatizzi, Katharina Brand, Bernard Canaud
Hyporesponsiveness to erythropoiesis-stimulating agent therapy in dialysis patients is poorly understood. Some studies report an improvement in the erythropoiesis-stimulating agent resistance index (ERI) with hemodiafiltration (HDF) versus high-flux hemodialysis (HD). We explored ERI dynamics in 38,340 incident HDF and HD patients treated in 22 countries over a 7-year period. Groups were matched by propensity score at baseline (6 months after dialysis initiation). The follow-up period (mean of 1.31 years) was stratified into 1 month intervals with delta analyses performed for key ERI-related parameters...
July 2016: Kidney International
https://www.readbyqxmd.com/read/27112531/pharmacodynamic-and-pharmacokinetic-equivalences-of-epoetin-hospira-and-epogen-%C3%A2-after-multiple-subcutaneous-doses-to-healthy-male-subjects
#15
Dennis Stalker, Atulkumar Ramaiya, Seema Kumbhat, Jeffrey Zhang, Susan Reid, Nancy Martin
PURPOSE: The purpose of this study was to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) equivalences of multiple doses of the proposed biosimilar Epoetin Hospira to the reference product Epogen(⁎), when each is administered three times per week over 28 days to healthy male subjects METHODS: This single center, open-label, randomized, parallel group study was conducted in 129 healthy male subjects. Subjects were randomized to receive 100 U/kg Epoetin Hospira or 100 U/kg Epogen, each administered subcutaneously 3 times per week over 28 days...
May 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27102553/combination-of-erythropoietin-and-tranexamic-acid-in-bilateral-simultaneous-total-hip-arthroplasty-a-randomised-controlled-trial
#16
Yuan-Gang Wu, Yi Zeng, Bin Shen, Hai-Bo Si, Fei Cao, Ti-Min Yang, Fu-Xing Pei
INTRODUCTION: This study aimed to evaluate whether the combination of erythropoietin (EPO) and tranexamic acid (TXA) exerted any additional benefits on the number of blood transfusions required and haematological parameters compared with TXA alone following primary bilateral simultaneous total hip arthroplasty. MATERIALS AND METHODS: We conducted a single-centre, prospective, randomised, and controlled trial at our hospital. Group EPO + TXA (n = 30) received daily subcutaneous injections EPO (10,000 IU) on preoperative days 1-4 and postoperative days 1-3...
July 25, 2016: Hip International: the Journal of Clinical and Experimental Research on Hip Pathology and Therapy
https://www.readbyqxmd.com/read/27088203/-above-standard-proceeding-in-nephrotic-syndrome-case-report
#17
Anna Matyjek, Dorota Brodowska-Kania, Stanisław Niemczyk
The nephrotic syndrome is characterized by the loss of many proteins, via the urinary system. It exceeds the bodies compensatory abilities and results in abnormalities in blood clotting system, particularly due to antithrombin deficiency. It significantly increases the risk of thromboembolic complications. A loss of erythropoietin and transferrin leads to anemia. Polycythemia is a rarely reported phenomenon. The case describes a 20-years old patient with massive nephrotic syndrome and polycythemia, complicated by a pulmonary embolism...
March 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/27068103/treatment-with-anti-il-6-receptor-antibody-prevented-increase-in-serum-hepcidin-levels-and-improved-anemia-in-mice-inoculated-with-il-6-producing-lung-carcinoma-cells
#18
Mariko Noguchi-Sasaki, Yusuke Sasaki, Yasushi Shimonaka, Kazushige Mori, Kaori Fujimoto-Ouchi
BACKGROUND: Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during inflammation. A mechanism linking cancer-related anemia and IL-6 through hepcidin production is suggested. To clarify the hypothesis that overproduction of IL-6 elevates hepcidin levels and contributes to the development of cancer-related anemia, we evaluated anti-IL-6 receptor antibody treatment of cancer-related anemia in an IL-6-producing human lung cancer xenograft model. METHODS: Nude mice were subcutaneously inoculated with cells of the IL-6-producing human lung cancer cell line LC-06-JCK and assessed as a model of cancer-related anemia...
2016: BMC Cancer
https://www.readbyqxmd.com/read/26984884/carbamylated-erythropoietin-outperforms-erythropoietin-in-the-treatment-of-aki-on-ckd-and-other-aki-models
#19
Florian E Tögel, Jon D Ahlstrom, Ying Yang, Zhuma Hu, Ping Zhang, Christof Westenfelder
Erythropoietin (EPO) may be a beneficial tissue-protective cytokine. However, high doses of EPO are associate with adverse effects, including thrombosis, tumor growth, and hypertension. Carbamylated erythropoietin (CEPO) lacks both erythropoietic and vasoconstrictive actions. In this study, we compared the renoprotective, hemodynamic, and hematologic activities and survival effects of identical EPO and CEPO doses in rat models of clinically relevant AKI presentations, including ischemia-reperfusion-induced AKI superimposed on CKD (5000 U/kg EPO or CEPO; three subcutaneous injections) and ischemia-reperfusion-induced AKI in old versus young animals and male versus female animals (1000 U/kg EPO or CEPO; three subcutaneous injections)...
November 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/26879839/long-term-effect-of-epoetin-alfa-on-clinical-and-biochemical-markers-in-friedreich-ataxia
#20
Francesco Saccà, Giorgia Puorro, Angela Marsili, Antonella Antenora, Chiara Pane, Carlo Casali, Christian Marcotulli, Giovanni Defazio, Daniele Liuzzi, Chiara Tatillo, Donata Maria Cambriglia, Giuseppe Schiano di Cola, Luigi Giuliani, Vincenzo Guardasole, Andrea Salzano, Antonio Ruvolo, Anna De Rosa, Antonio Cittadini, Giuseppe De Michele, Alessandro Filla
BACKGROUND: Friedreich ataxia is an autosomal recessive disease with no available therapy. Clinical trials with erythropoietin in Friedreich ataxia patients have yielded conflicting results, and the long-term effect of the drug remains unknown. METHODS: We designed a double-blind, placebo-controlled, multicenter trial to test the efficacy of epoetin alfa on 56 patients with Friedreich ataxia. The primary endpoint of the study was the effect of epoetin alfa on peak oxygen uptake (VO2 max) at the cardiopulmonary exercise test...
May 2016: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
21174
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"